Standard of Care and Medications for EMA

Treating Epilepsy with Myoclonic Absences (EMA) is a unique challenge because the condition involves multiple types of “misfiring” in the brain. Unlike more common childhood epilepsies that might only cause staring spells, EMA often requires a “broad-spectrum” approach—medications that can treat both the absence (staring) and the myoclonus (jerking) at the same time ^[1][2].

Critical Warning: Never stop or change your child’s antiseizure medication abruptly or without consulting the prescribing doctor. Sudden withdrawal can trigger severe, prolonged, and life-threatening seizures.

First-Line Treatment Options

Because children with EMA often have more than one type of seizure—such as myoclonic absences and generalized tonic-clonic (“grand mal”) seizures—doctors typically choose medications that can cover many seizure types at once.

• Valproate (Valproic Acid): This is frequently the first medication tried for EMA. In small observational studies, many children who achieved seizure freedom were taking valproate ^[2]. It works across a wide range of generalized seizure types ^[1].
  • Important Safety Note: Valproate carries major risks of fetal malformation and neurodevelopmental issues if taken during pregnancy. Strict reproductive counseling applies to any person who could become pregnant ^[3]. For the child taking it, major risks include hepatotoxicity (liver damage), pancreatitis, thrombocytopenia (low platelets), high ammonia, and metabolic/weight changes. Close blood monitoring is required.
• Lamotrigine: This is often used, sometimes as an “add-on” alongside valproate, as the two are frequently used together ^[4][5].
  • Important Safety Note: Valproate significantly increases the levels of lamotrigine in the blood. Therefore, lamotrigine must be started at an extremely low dose and increased very slowly to avoid a severe, life-threatening skin rash. If your child develops a fever, mouth sores, blistering, or any spreading rash, seek urgent medical advice. Note also that lamotrigine can occasionally worsen myoclonic seizures in some patients.
• Ethosuximide: While this is the “gold standard” for typical Childhood Absence Epilepsy (CAE), it is often not adequate for EMA when used alone ^[6]. This is because ethosuximide treats staring spells well but does not protect against generalized tonic-clonic or myoclonic seizures ^[6][7].

A Vital Warning: Medicines That May Worsen Seizures

In EMA, choosing the wrong medicine can be as significant as choosing the right one. Certain medications used to treat focal epilepsy can actually aggravate generalized myoclonic and absence seizures ^[8][9]. If you observe worsening seizures after a new medication is started, contact your specialist for urgent review, but do not stop the medication on your own.

Medications that may provoke or worsen myoclonic/generalized seizures include:

• Carbamazepine
• Oxcarbazepine
• Phenytoin
• Vigabatrin
• Tiagabine
• Gabapentin and Pregabalin ^[9]

Understanding Drug Resistance

Unfortunately, EMA is known for being difficult to treat. About half of children with EMA may have drug-resistant epilepsy, which is defined as failing to achieve seizure freedom after trying two appropriately chosen medications at the right doses ^[2][10].

If your child’s seizures continue despite two medication trials, your care team may discuss other specialized options:

• Dietary Therapy: The ketogenic diet or the modified Atkins diet are medically supervised, high-fat diets that can significantly reduce seizures in some children with drug-resistant epilepsy ^[11][12].
• Vagus Nerve Stimulation (VNS): A small device implanted under the skin that sends regular, mild pulses of electrical energy to the brain via the vagus nerve ^[13].
• Specialist Referral: At this stage, a referral to a comprehensive pediatric epilepsy center (often called a Level 4 center in the US) is critical ^[14]. These centers have specialized teams—including dietitians, surgeons, and geneticists—who focus entirely on children with complex epilepsy.

While the path to the right treatment can be a process of trial and error, identifying the broad-spectrum medications that work best while avoiding those that worsen myoclonus is the foundation of a good management plan.